Enhanced drug delivery in transdermal systems
AssigneeNoven Pharmaceuticals, Inc.
InventorsDavid Houze, Viet Nguyen
Life of this patent
Estimating the term…
Loading patent…
AssigneeNoven Pharmaceuticals, Inc.
InventorsDavid Houze, Viet Nguyen
Estimating the term…
A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a drug that includes a parent drug and a prodrug; and a pharmaceutically acceptable carrier, wherein the parent drug and prodrug are individually present in an amount sufficient for a pharmacological effect. In a preferred embodiment, the admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid:corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive. In another preferred embodiment, the parent drug is an ACE inhibitor such as ramipril and the prodrug is an ACE inhibitor prodrug such as ramipril ethyl and/or methyl ester.
1-52. (canceled)
A method for controlling the melting point of a drug in a composition for transdermal delivery, comprising providing a pharmaceutically acceptable carrier comprising a pressure-sensitive adhesive and a combination of a drug and a corresponding pro-drug, wherein the melting point of the drug/pro-drug combination is lower than the melting points of each of the drug or pro-drug alone.
A method for controlling the melting point of a drug in a composition for transdermal delivery, comprising providing a pharmaceutically acceptable carrier comprising a pressure-sensitive adhesive and a combination of a drug and a corresponding pro-drug, wherein the melting point of the drug/pro-drug combination is higher than the melting points of each of the drug and pro-drug alone.
Dependencies are inferred from the claim text.